Clinical Progress in Gene Therapy: Sustained Partial Correction of the Bleeding Disorder in Patients Suffering from Severe Hemophilia B

Abstract

Get full access to this article

View all access options for this article.

References

Axelrod

J.H.

, Read

M.S.

, Brinkhous

K.M.

, Verma

I.M.

1990. Phenotypic correction of factor IX deficiency in skin fibroblasts of hemophilic dogs. Proc. Natl. Acad. Sci. U.S.A., 87:5173–5177.

Gao

G.P.

, Alvira

M.R.

, Wang

et al. 2002. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U.S.A., 99:11854–11859.

High

K.A.

2011. Gene therapy for haemophilia: a long and winding road. J. Thromb. Haemost., 9,Suppl 1:2–11.

Jiang

, Pierce

G.F.

, Ozelo

M.C.

et al. 2006. Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol. Ther., 14:452–455.

Kay

M.A.

, High

1999. Gene therapy for the hemophilias. Proc. Natl. Acad. Sci. U.S.A., 96:9973–9975.

Kay

M.A.

, Manno

C.S.

, Ragni

M.V.

et al. 2000. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet., 24:257–261.

Manno

C.S.

, Pierce

G.F.

, Arruda

V.R.

et al. 2006. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med., 12:342–347.

Mátrai

, Chuah

M.K.

, VandenDriessche

2010. Preclinical and clinical progress in hemophilia gene therapy. Curr. Opin. Hematol., 17:387–392.

McCarty

D.M.

, Monahan

P.E.

, Samulski

R.J.

2001. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther., 8:1248–1254.

10.

McCarty

D.M.

, Fu

, Monahan

P.E.

et al. 2003. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther., 10:2112–2118.

11.

Mingozzi

, Liu

Y.L.

, Dobrzynski

et al. 2003. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J. Clin. Invest., 111:1347–1356.

12.

Mingozzi

, Maus

M.V.

, Hui

D.J.

et al. 2007. CD8⁺ T-cell responses to adeno-associated virus capsid in humans. Nat. Med., 13:419–422.

13.

Nathwani

A.C.

, Gray

J.T.

, Ng

C.Y.

et al. 2006. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood, 107:2653–2661.

14.

Nathwani

, Tuddenham

E.G.D.

, Rangarajan

et al. 2011. Adenovirus-associated virus vector–mediated gene transfer in hemophilia B. N. Engl. J. Med.[Epub ahead of print]

15.

Vandenberghe

L.H.

, Wang

, Somanathan

et al. 2006. Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. Nat. Med., 12:967–971.

16.

VandenDriessche

, Thorrez

, Acosta-Sanchez

et al. 2007. Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J. Thromb. Haemost., 5:16–24.

17.

Ward

N.J.

, Buckley

S.M.

, Waddington

S.N.

et al. 2011. Codon optimization of human factor VIII cDNAs leads to high-level expression. Blood, 117:798–807.